Abstract Development of new drugs is of high interest for the field of cardiac and
cardiovascular diseases, which are a dominant cause of death worldwide. Before being …

In recent years, drug development costs have soared, primarily due to the failure of
preclinical animal and cell culture models, which do not directly translate to human …

Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit
in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF). We …

Trastuzumab (Herceptin®), a monoclonal antibody against the ErbB2 (HER2) receptor, has
significantly improved clinical outcomes for HER2+ breast cancer patients. However, the …

Abstract Purpose of Review This review explores the cardiovascular toxicity associated with
cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It …

Chagas disease (ChD) is one of the most neglected tropical diseases, with cardiomyopathy
being the main cause of death in Trypanosoma cruzi-infected patients. As the parasite …

Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years.
Although more targeted than conventional chemotherapy, TKIs exhibit substantial …

Stem cell based toxicity prediction plays a very important role in the development of the
drug. Unexpected adverse effects of the drugs during clinical trials are a major reason for the …

We describe a method for protein quantification and for mRNA quantification in small sample
quantities of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) …

TOP2 inhibitors (TOP2i) are effective drugs for breast cancer treatment. However, they can
cause cardiotoxicity in some women. The most widely used TOP2i include anthracyclines …